Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Ann Hematol ; 103(1): 175-183, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37796339

RESUMEN

Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUVmax], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (ΔSUVmax, ΔTMTV and ΔTLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4-5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUVmax, TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among ΔSUVmax, ΔTMTV and ΔTLG, only a ΔSUVmax ≥ 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11-0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (ΔSUVmax ≥ 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the ΔSUVmax to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.


Asunto(s)
Enfermedad de Hodgkin , Humanos , Adulto , Estudios Retrospectivos , Enfermedad de Hodgkin/diagnóstico por imagen , Enfermedad de Hodgkin/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Fluorodesoxiglucosa F18 , Bleomicina , Dacarbazina , Doxorrubicina , Vinblastina , Pronóstico , Tomografía Computarizada por Tomografía de Emisión de Positrones , Tomografía de Emisión de Positrones
2.
J Chemother ; 30(6-8): 375-379, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30663548

RESUMEN

While Burkitt lymphoma (BL) is an aggressive subtype of non-Hodgkin lymphoma more prevalent in tropical areas, few studies on BL have been conducted in Latin America. Here, we evaluate the clinical presentation and outcomes of an adapted LMB regimen for adults with sporadic BL. We retrospectively evaluated hospital records from University of São Paulo (USP) between 1999 and 2017. Thirty-six patients were included, the median age was 33.5 years and 69% (25) were male. Most patients presented advanced stage disease (81%), 8% had CNS disease, and the majority belonged to LMB group B (75% (27)). Three patients died during the induction phase, and the remaining patients (33) achieved complete response. There was one relapse over a median follow-up of 6 years. Overall survival estimated at 5 years was 89%. We conclude that an adapted LMB protocol is safe and feasible in Brazil.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Burkitt/tratamiento farmacológico , Adolescente , Adulto , Anciano , Brasil , Ciclofosfamida/uso terapéutico , Citarabina/uso terapéutico , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Metotrexato/uso terapéutico , Persona de Mediana Edad , Pacientes Ambulatorios , Estudios Retrospectivos , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA